August 6th 2020
In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.
August 3rd 2020
In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.
July 30th 2020
In our exclusive interview, Courtney DiNardo, MD, MSCE, discusses the role of venetoclax in acute myeloid leukemia and explains the significance of the results of the VIALE-A trial.
July 27th 2020
In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.
July 23rd 2020
In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.
July 20th 2020
In our exclusive interview, Alexander Drilon, MD provided background on use of targeted therapy in advanced non–small cell lung cancer, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.
July 16th 2020
In our exclusive interview, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, discuss key takeaways from the 2020 ASCO Virtual Scientific Program on exciting efforts being made in the field of sarcoma.
July 13th 2020
In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.
July 9th 2020
In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.
July 6th 2020
Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.
